Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avutometinib - Verastem Oncology

Next Previous
Drug Profile

Avutometinib - Verastem Oncology

Alternative Names: AVMAPKI FAKZYNJA CO-PACK; AVMAPKI™; CH 5127566; CH-5126766; CKI-27; R-7304; Raf/MEK inhibitor VS-6766; RG 7304; RO-5126766; VS-6766

Latest Information Update: 05 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Amgen; Eli Lilly and Company; Verastem Oncology
  • Class Antineoplastics; Benzopyrans; Ethers; Fluorinated hydrocarbons; Ketones; Pyridines; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase II Colorectal cancer; Gastric cancer; Gynaecological cancer; Non-small cell lung cancer; Thyroid cancer; Uveal melanoma
  • Phase I/II Adenocarcinoma; Glioblastoma; HER2 negative breast cancer; Malignant melanoma; Solid tumours
  • Phase I Multiple myeloma
  • Preclinical Neurofibrosarcoma

Most Recent Events

  • 29 Dec 2025 Verastem Oncology terminates phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in the US, Belgium, France, Netherlands, Spain and United Kingdom (NCT05074810)
  • 05 Nov 2025 University of Chicago reinitiates a phase-I/II trial in Colorectal cancer (Late-stage disease, Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT05200442)
  • 15 Oct 2025 Royal Marsden NHS Foundation Trust completes a phase-I trial in Solid tumours and Multiple myeloma in United Kingdom (PO) (NCT02407509)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top